HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech Web site

This article was originally published in The Rose Sheet

Executive Summary

Nanotechnology Consumer Products Inventory is "the first and only publicly accessible online inventory of nanotechnology consumer products," including items like creams and sunscreens, The Project on Emerging Nanotechnologies at the Woodrow Wilson International Center for Scholars says. Unveiled March 10, inventory, which features information on 212 manufacturer-identified nano products, is available at Nanotechproject.org/consumerproducts. According to the project, there are 31 cosmetic products on the market containing nanotechnology. "The U.S. is the overwhelming leader in consumer nanotechnology product development with 126; East Asia and Europe follow with 42 and 35 nano products respectively," the group found...

You may also be interested in...



Health Products Lead Rapidly Expanding Nanotechnology Product List

Health & fitness products including cosmetics and personal-care items dominate the landscape of nano-engineered consumer goods, according to the Project on Emerging Nanotechnologies, overseen by the Woodrow Wilson International Center for Scholars

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel